No benefit seen from adjuvant celecoxib in ERBB2-negative breast cancer
(HealthDay)—For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with placebo, according to a ...
Jul 16, 2021
0
1